How I treat paroxysmal nocturnal hemoglobinuria.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
11 03 2021
Historique:
received: 01 07 2020
accepted: 28 08 2020
pubmed: 30 1 2021
medline: 27 7 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, clonal, complement-mediated hemolytic anemia with protean manifestations. PNH can present as a hemolytic anemia, a form of bone marrow failure, a thrombophilia, or any combination of the above. Terminal complement inhibition is highly effective for treating intravascular hemolysis from PNH and virtually eliminates the risk of thrombosis, but is not effective for treating bone marrow failure. Here, I present a variety of clinical vignettes that highlight the clinical heterogeneity of PNH and the attributes and limitations of the 2 US Food and Drug Administration-approved C5 inhibitors (eculizumab and ravulizumab) to treat PNH. I review the concept of pharmacokinetic and pharmacodynamic breakthrough hemolysis and briefly discuss new complement inhibitors upstream of C5 that are in clinical development. Last, I discuss the rare indications for bone marrow transplantation in patients with PNH.

Identifiants

pubmed: 33512400
pii: S0006-4971(21)00169-5
doi: 10.1182/blood.2019003812
pmc: PMC7955407
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Complement Inactivating Agents 0
eculizumab A3ULP0F556
ravulizumab C3VX249T6L

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1304-1309

Informations de copyright

© 2021 by The American Society of Hematology.

Références

Front Immunol. 2019 Jun 14;10:1157
pubmed: 31258525
Blood. 2019 Feb 7;133(6):530-539
pubmed: 30510080
J Lipid Res. 2016 Jan;57(1):6-24
pubmed: 26563290
J Clin Invest. 2020 May 1;130(5):2152-2163
pubmed: 32310222
N Engl J Med. 2006 Sep 21;355(12):1233-43
pubmed: 16990386
Cytometry B Clin Cytom. 2010 Jul;78(4):211-30
pubmed: 20533382
Cell. 1997 Jan 10;88(1):1-4
pubmed: 9019395
Lancet. 1996 Aug 31;348(9027):573-7
pubmed: 8774569
Nat Biotechnol. 2007 Nov;25(11):1256-64
pubmed: 17989688
Haematologica. 2005 Dec;90(12 Suppl):ECR40
pubmed: 16464755
Haematologica. 2012 Nov;97(11):1666-73
pubmed: 22689687
Br J Haematol. 2020 Jun;189(5):802-805
pubmed: 32166737
Blood. 2017 Feb 23;129(8):970-980
pubmed: 28028023
N Engl J Med. 2015 Sep 10;373(11):1032-9
pubmed: 26352814
Blood Coagul Fibrinolysis. 2018 Apr;29(3):243-251
pubmed: 29517503
Br J Haematol. 2013 Jul;162(1):62-73
pubmed: 23617322
Br J Haematol. 2020 Nov;191(3):476-485
pubmed: 32449174
Blood. 2011 Jun 23;117(25):6786-92
pubmed: 21460245
Blood. 2007 Dec 1;110(12):4123-8
pubmed: 17702897
Blood. 2013 Jun 20;121(25):4985-96; quiz 5105
pubmed: 23610373
Br J Haematol. 2019 Apr;185(2):297-310
pubmed: 30768680
EBioMedicine. 2016 Feb 06;5:175-82
pubmed: 27077125
J Clin Invest. 2014 Oct;124(10):4529-38
pubmed: 25244093
Haematologica. 2017 Mar;102(3):466-475
pubmed: 27810992
JAMA. 2005 Apr 6;293(13):1653-62
pubmed: 15811985
Haematologica. 2020 Jan 16;106(1):230-237
pubmed: 31949012
Eur J Haematol. 2014 Jun;92(6):467-70
pubmed: 24612308
Br J Haematol. 2004 Jul;126(1):133-8
pubmed: 15198744
Blood. 2009 Apr 23;113(17):4094-100
pubmed: 19179465
Semin Immunopathol. 2018 Jan;40(1):103-111
pubmed: 28900713
Clin Exp Immunol. 1991 Oct;86 Suppl 1:57-62
pubmed: 1934605
Blood. 2008 Oct 15;112(8):3099-106
pubmed: 18535202
Obstet Gynecol Surv. 2006 Sep;61(9):593-601
pubmed: 16919177
N Engl J Med. 1995 Nov 9;333(19):1253-8
pubmed: 7566002
Blood. 2008 Feb 15;111(4):1840-7
pubmed: 18055865
J Immunol. 2006 Oct 1;177(7):4794-802
pubmed: 16982920
Biol Blood Marrow Transplant. 2018 Dec;24(12):e26-e30
pubmed: 30055352
Am J Hematol. 2009 Oct;84(10):699-701
pubmed: 19705437
Haemostasis. 2000 May-Jun;30(3):103-17
pubmed: 11014960
J Blood Med. 2016 May 30;7:107-10
pubmed: 27313483
Stem Cells Transl Med. 2013 Nov;2(11):819-29
pubmed: 24113066
Blood Adv. 2020 Apr 28;4(8):1770-1779
pubmed: 32343796
Nat Rev Dis Primers. 2017 May 18;3:17028
pubmed: 28516949
Blood. 2017 Aug 17;130(7):891-899
pubmed: 28630122
Blood. 2019 Feb 7;133(6):540-549
pubmed: 30510079
Mol Immunol. 2010 Apr;47(7-8):1500-6
pubmed: 20181396
Blood. 2009 Jun 25;113(26):6522-7
pubmed: 19372253
Am J Clin Pathol. 2000 Sep;114(3):459-66
pubmed: 10989647
Blood. 2006 Dec 15;108(13):4232-6
pubmed: 16940417
Blood. 2010 Aug 5;116(5):687-92
pubmed: 20395414

Auteurs

Robert A Brodsky (RA)

Division of Hematology, Johns Hopkins Medicine, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH